Cellular therapy services provided by blood centers and hospitals in the United States, 1999: An analysis from the Nationwide Blood Collection and Utilization Survey

Transfusion

Volumn 44, Issue 4, 2004, Pages 539-546

  Read, Elizabeth J ^a   Sullivan, Marian T ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD BANK; BLOOD SAMPLING; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; BREAST CANCER; CELL CULTURE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL; HUMAN; HUMAN CELL; LYMPHOCYTE TRANSFER; NATIONWIDE BLOOD COLLECTION AND UTILIZATION SURVEY; PERIPHERAL BLOOD STEM CELL; SURGERY; UMBILICAL CORD BLOOD; UNITED STATES;

BLOOD BANKS; BONE MARROW; FETAL BLOOD; HEMATOPOIETIC STEM CELLS; HOSPITALS; HUMANS; LICENSURE; LYMPHOCYTES; QUESTIONNAIRES; STEM CELL TRANSPLANTATION; TISSUE AND ORGAN PROCUREMENT; UNITED STATES;

EID: 1842583044     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2003.03286.x     Document Type: Article

References (15)

1. Horowitz MM. Uses and growth of hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic cell transplantation. 2nd ed. Malden (MA): Blackwell Science, 1999:12-8.
2. International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry. Report on state of the art in blood and marrow transplantation-the IBMTR/ABMTR Summary slides 2000 with guide [Internet]. IBMTR/ABMTR Newslett 2000;7:1-12. Available from: http//www.ibmtr.org/newsletter/pdf/Y2K_nltr.pdf
3. International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry. Report on state of the art in blood and marrow transplantation-the IBMTR/ABMTR Summary slides 2002 with guide [Internet]. IBMTR/ABMTR Newsletter 2002;9:1-11. Available from: http://www.ibmtr.org/newsletter/pdf/2002Feb.pdf
4. Sullivan MT, McCullough J, Schreiber GB, Wallace EL. Blood collection and transfusion in the United States in 1997. Transfusion 2002;42:1253-60.
5. Stroncek D, Anderlini P. Mobilized PBPC concentrates: a maturing component. Transfusion 2001;41:168-71.
6. Grewal SS, Barker JN, Davies SM, Wagner JE. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood 2003;101:4233-44.
7. Kohn DB, Weinberg KI, Nolta JA, et al. Engraftment of gene-modified cells from umbilical cord blood in neonates with adenosine deaminase deficiency. Nat Med 1995;1:1017-23.
8. Cord blood banking for potential future transplantation. subject review. American Academy of Pediatrics. Work Group on Cord Blood Banking, Pediatrics 1999;104:116-8.
9. Lecchi L, Ratti I, Lazzari L, Rebulla P, Sirchia G. Reasons for discard of umbilical cord blood units before cryopreservation. Transfusion 2000;40:122-4.
10. Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993;82:2310-8.
11. Childs R, Barrett J. Nonmyeloablative stem cell transplantation for solid tumors: expanding the application of allogeneic immunotherapy. Semin Hematol 2002;39: 63-71.
12. Gabrilovich DI. Dendritic cell vaccines for cancer treatment. Curr Opin Mol Ther 2002;4:452-8.
13. Solomon SR, Tran T, Carter CS, et al. Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. Cytotherapy 2002;4:395-406.
14. Human cells, tissues, and cellular tissue-based products: establishment registration and listing. Food and Drug Administration, HHS. Final rule. Fed Regist 2001;66:5447-69.
15. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Phase III randomized trial of high dose chemotherapy and stem cell support shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil for women with metastatic breast cancer who are responding to conventional induction chemotherapy: the Philadelphia intergroup study (PBT-1). Proc Am Soc Clin Oncol 1999; 18:1a.